ArticleCell reports. Medicine2023

Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma.

Qiuzhong Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.